DE69525366D1 - Die verwendung von bmp-protein-rezeptor komplexen für das screening von substanzen aus dem knochenmetabolismus und zellen die mit einem typ i- und typ ii-bmp-rezeptor co-transfiziertsind - Google Patents

Die verwendung von bmp-protein-rezeptor komplexen für das screening von substanzen aus dem knochenmetabolismus und zellen die mit einem typ i- und typ ii-bmp-rezeptor co-transfiziertsind

Info

Publication number
DE69525366D1
DE69525366D1 DE69525366T DE69525366T DE69525366D1 DE 69525366 D1 DE69525366 D1 DE 69525366D1 DE 69525366 T DE69525366 T DE 69525366T DE 69525366 T DE69525366 T DE 69525366T DE 69525366 D1 DE69525366 D1 DE 69525366D1
Authority
DE
Germany
Prior art keywords
bmp
kinase protein
receptor kinase
type
bmp receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69525366T
Other languages
English (en)
Other versions
DE69525366T2 (de
Inventor
Susan Rosenbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of DE69525366D1 publication Critical patent/DE69525366D1/de
Application granted granted Critical
Publication of DE69525366T2 publication Critical patent/DE69525366T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69525366T 1994-11-04 1995-10-30 Die verwendung von bmp-protein-rezeptor komplexen für das screening von substanzen aus dem knochenmetabolismus und zellen die mit einem typ i- und typ ii-bmp-rezeptor co-transfiziertsind Expired - Fee Related DE69525366T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33417894A 1994-11-04 1994-11-04
US08/462,467 US6210899B1 (en) 1994-11-04 1995-06-05 Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
PCT/US1995/014027 WO1996014579A1 (en) 1994-11-04 1995-10-30 The use of a bmp protein receptor complex for screening bone metabolism actives and cells co-transfected with a type ii bmp receptor and a type i bmp receptor

Publications (2)

Publication Number Publication Date
DE69525366D1 true DE69525366D1 (de) 2002-03-21
DE69525366T2 DE69525366T2 (de) 2002-11-07

Family

ID=26989071

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69525366T Expired - Fee Related DE69525366T2 (de) 1994-11-04 1995-10-30 Die verwendung von bmp-protein-rezeptor komplexen für das screening von substanzen aus dem knochenmetabolismus und zellen die mit einem typ i- und typ ii-bmp-rezeptor co-transfiziertsind

Country Status (8)

Country Link
US (2) US6210899B1 (de)
EP (1) EP0789844B1 (de)
JP (1) JP3527248B2 (de)
AT (1) ATE213064T1 (de)
AU (1) AU710559B2 (de)
DE (1) DE69525366T2 (de)
DK (1) DK0789844T3 (de)
WO (1) WO1996014579A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306622B1 (en) * 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
WO1996018735A2 (en) * 1994-12-14 1996-06-20 Amgen Boulder Inc. Tgf-beta superfamily type ii receptor having binding affinity for bone morphogenic protein (bmp)
JP2000514777A (ja) * 1995-08-14 2000-11-07 クリエイティブ バイオモレキュールズ，インコーポレイテッド 骨形成タンパク質（ｏｐ−１）およびそのアナログの細胞表面レセプターａｌｋ−１およびそのアナログへの結合
IL132922A0 (en) * 1997-05-16 2001-03-19 Procter & Gamble The use of a bone morphogenetic protein (bmp) receptor complex for screening
AU2003230904A1 (en) * 2002-04-12 2003-10-27 Trustees Of Boston University Methods for lightening skin and hair
EP2789342A1 (de) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. Verbindungen im Zusammenhang mit TDF und Analoga davon
ES2537527T3 (es) 2005-09-20 2015-06-09 Thrasos Innovation, Inc. Compuestos relacionados con el TDF y análogos de los mismos
US20070293587A1 (en) * 2006-05-23 2007-12-20 Haley Jeffrey T Combating sinus, throat, and blood infections with xylitol delivered in the mouth
WO2010051032A1 (en) * 2008-10-31 2010-05-06 Synthes Usa, Llc Method and device for activating stem cells
KR101451340B1 (ko) * 2012-08-02 2014-10-15 (주)애드바이오텍 모발 생장 촉진용 조성물
KR20240001181A (ko) * 2021-04-28 2024-01-03 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 Covid-19 및 신종 변이의 치료 및 예방을 위한 항체

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
CA2002011A1 (en) 1988-11-14 1990-05-14 Anthony F. Purchio Normal human growth regulatory receptor for tgf-beta
US5168050A (en) 1990-05-24 1992-12-01 Genentech, Inc. Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion
AU654724B2 (en) 1991-05-10 1994-11-17 Salk Institute For Biological Studies, The Cloning and recombinant production of receptor(s) of the activin/TGF-beta superfamily
US5216126A (en) 1991-06-19 1993-06-01 Genentech, Inc. Receptor polypeptides and their production and uses
JP4124815B2 (ja) 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
WO1993019177A1 (en) 1992-03-18 1993-09-30 The General Hospital Corporation FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
ATE234920T1 (de) 1992-11-17 2003-04-15 Ludwig Inst Cancer Res Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6248554B1 (en) 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor

Also Published As

Publication number Publication date
WO1996014579A1 (en) 1996-05-17
AU3971395A (en) 1996-05-31
ATE213064T1 (de) 2002-02-15
EP0789844B1 (de) 2002-02-06
US7105290B2 (en) 2006-09-12
DK0789844T3 (da) 2002-05-27
US6210899B1 (en) 2001-04-03
EP0789844A1 (de) 1997-08-20
JPH10510047A (ja) 1998-09-29
DE69525366T2 (de) 2002-11-07
US20030096296A1 (en) 2003-05-22
JP3527248B2 (ja) 2004-05-17
AU710559B2 (en) 1999-09-23

Similar Documents

Publication Publication Date Title
Guijt‐van Duijn et al. Recent advances in affinity capillary electrophoresis
Klotz Ligand-receptor energetics: a guide for the perplexed
Williams et al. Platelet-derived growth factor stimulates mouse 3T3 cell mitogenesis and leukocyte chemotaxis through different structural determinants.
Heegaard Applications of affinity interactions in capillary electrophoresis
ES8405157A1 (es) Procedimiento de analisis inmunologico.
Bauer et al. Macromolecular association of ADP-ribosyltransferase and its correlation with enzymic activity
DE69525366T2 (de) Die verwendung von bmp-protein-rezeptor komplexen für das screening von substanzen aus dem knochenmetabolismus und zellen die mit einem typ i- und typ ii-bmp-rezeptor co-transfiziertsind
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
EP1190231A4 (de) System zur elektrochemischen quantitativen analyse von analyten in einer festphase
EP1965213A3 (de) Microarrays und ihre Verwendungen
AU3395084A (en) Polypeptide-induced monoclonal receptors to protein ligands
DE69818104D1 (de) Verwendung eines neuen kalibrators in einem verfahren sowie eine vorrichtung und ein testkit mit diesem kalibrator
ATE461450T1 (de) Verwendung von kontrollflächen zur detektion von störproben in einem nachweisverfahren
EP0873998A3 (de) Rezeptor-Protein und seine Verwendung
WO2011010304A2 (en) Method for preparing molecularly imprinted polymers and uses thereof
ATE239274T1 (de) Proteom-analyse zum charakterisieren von auf- und abgeregelten proteinen in biologischen proben
Chen et al. The synthesis and screening of a combinatorial peptide library for affinity ligands for glycosylated haemoglobin
Mikŝík et al. Change in the amount of ε-hexosyllysine, UV absorbance, and fluorescence of collagen with age in different animal species
Tas et al. Protein staining methods in quantitative cytochemistry
Sugawara et al. Construction of a peptide with an electroactive daunomycin like a pendant arm to detect ovalbumin
Westwood et al. Group-specific component: A review of the isoelectric focusing methods and auxiliary methods available for the separation of its phenotypes
CN103033628A (zh) 制备个体全蛋白质组芯片的方法及其应用
Abuknesha et al. Multianalyte immunoanalysis: practical aspects of manufacturing transducers
Hackman Biochemical methods (proteins)
SU894574A1 (ru) Способ контрол биосинтеза белка в растворе

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee